MedTrace Logo

Prevalence of Anticipatory Nausea and Vomiting in Cancer Patients Exposed to Highly Emetogenic Chemotherapy

NCT04785495 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-03-08

No results posted yet for this study

Summary

Chemotherapy induced nausea and vomiting are common adverse events related to oncologic treatments. It can have deleterious effect on patients' quality of life and could lead to dose reductions and/or discontinuation of treatment. This study aims to quantify the prevalence of nausea and vomiting induced by highly emetogenic chemotherapy in patients who had adequate antiemetic prophylaxis, also to describe the epidemiologic profile and identify predisposing factors.

Conditions

  • Chemotherapy-induced Nausea and Vomiting

Interventions

OTHER

Quality-of-life assessment

Patients will be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero (before the application of chemotherapy) and then after 6 day, after application of chemotherapy.

Sponsors & Collaborators

  • Instituto Brasileiro de Controle do Cancer

    lead OTHER

Principal Investigators

  • Camilla Vieira de Rebouças, MD · Instituto Brasileiro de Controle do Cancer

  • Louize Caroline Marques Oliveira, MD · Instituto Brasileiro de Controle do Cancer

  • Rafaela de Brito Alves, MD · Instituto Brasileiro de Controle do Cancer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-12
Primary Completion
2021-08-31
Completion
2021-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04785495 on ClinicalTrials.gov